P. Paschka, G. Marcucci, and A. Ruppert, Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study, Journal of Clinical Oncology, vol.24, issue.24, pp.3904-3911, 2006.
DOI : 10.1200/JCO.2006.06.9500

S. Schnittger, T. Kohl, and T. Haferlach, KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival, Blood, vol.107, issue.5, pp.1791-1799, 2006.
DOI : 10.1182/blood-2005-04-1466

A. Advani, C. Rodriguez, and T. Jin, Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML, Leukemia Research, vol.32, issue.6, pp.913-918, 2008.
DOI : 10.1016/j.leukres.2007.08.019

F. Belloc, K. Airiau, and M. Jeanneteau, The stem cell factor???c-KIT pathway must be inhibited to enable apoptosis induced by BCR???ABL inhibitors in chronic myelogenous leukemia cells, Leukemia, vol.25, issue.4, pp.679-685, 2009.
DOI : 10.1056/NEJMoa055104

S. Hirota, K. Isozaki, and Y. Moriyama, Gain-of-Function Mutations of c-kit in Human Gastrointestinal Stromal Tumors, Science, vol.279, issue.5350, pp.577-580, 1998.
DOI : 10.1126/science.279.5350.577

K. Inokuchi, H. Yamaguchi, and M. Tarusawa, Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia ??? potential clinical significance, Leukemia, vol.16, issue.2, pp.170-177, 2002.
DOI : 10.1038/sj.leu.2402341

M. Malaise, D. Steinbach, and S. Corbacioglu, Clinical implications of c-Kit mutations in acute myelogenous leukemia, Current Hematologic Malignancy Reports, vol.101, issue.2, pp.77-82, 2009.
DOI : 10.1007/s11899-009-0011-8

N. Boissel, H. Leroy, and B. Brethon, Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML), Leukemia, vol.102, issue.6, pp.965-970, 2006.
DOI : 10.1038/sj.leu.2404188

B. Goemans, C. Zwaan, and M. Miller, Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia, Leukemia, vol.105, issue.9, pp.1536-1542, 2005.
DOI : 10.1038/sj.leu.2403870

H. Al-ali, M. Heinrich, and T. Lange, High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib, The Hematology Journal, vol.5, issue.1, pp.55-60, 2004.
DOI : 10.1038/sj.thj.6200319

S. Menif, S. Zarrouki, and R. Jeddi, Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia, Pathologie Biologie, vol.57, issue.5, pp.388-391, 2009.
DOI : 10.1016/j.patbio.2007.12.010
URL : https://hal.archives-ouvertes.fr/pasteur-01375194

E. Reiter, H. Greinix, and S. Brugger, Long term follow up after allogeneic stem cell transplantation for chronic myelogenous leukemia, Bone Marrow Transplant, vol.22, pp.86-88, 1998.

M. Yaghmaie, S. Ghaffari, and A. Ghavamzadeh, Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia, Arch Iran Med, vol.11, pp.247-251, 2008.

R. Perego, M. Costantini, and G. Cornacchini, The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia, European Journal of Cancer, vol.36, issue.11, pp.1395-1401, 2000.
DOI : 10.1016/S0959-8049(00)00128-3

W. Prejzner, Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course prognostic indexes and survival in patients with chronic myeloid leukemia, Med Sci Monit, vol.8, pp.191-197, 2002.

O. Tetsu, J. Phuchareon, and A. Chou, Mutations in the c-Kit Gene Disrupt Mitogen-Activated Protein Kinase Signaling during Tumor Development in Adenoid Cystic Carcinoma of the Salivary Glands, Neoplasia, vol.12, issue.9, pp.708-717, 2010.
DOI : 10.1593/neo.10356

A. Mital, A. Piskorz, and K. Lewandowski, A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib, European Journal of Haematology, vol.42, issue.6, pp.531-535, 2011.
DOI : 10.1111/j.1600-0609.2011.01598.x